Indications for: DENGVAXIA
Immunization against dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 9–16 years of age with laboratory-confirmed previous dengue infection and living in endemic areas.
Limitations of Use:
Not for use if not previously infected by any dengue virus serotype or for whom this information is unknown. Safety and efficacy have not been established in individuals living in dengue non-endemic areas who travel to dengue endemic areas.
>16yrs: not established.
<9yrs: not established. Give by SC inj only. ≥9yrs to ≤16yrs: one 0.5mL dose at month 0, 6, and 12.
Severe immunodeficiency or immunosuppression due to disease or therapy.
Increased risk of severe dengue infection following Dengvaxia if not previously infected by dengue virus. Evaluate for prior dengue infection; avoid vaccination if not previously infected or unknown. Have appropriate medical treatment and supervision available to manage allergic reactions. Limitations of vaccine effectiveness; advise to continue personal protection measures against mosquito bites after vaccination. Labor & delivery. Pregnancy. Nursing mothers.
Immunosuppressants (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, high-dose steroids) may reduce immune response to Dengvaxia. May cause false (–) results of tuberculin purified protein derivative (PPD) test sensitivity; give tuberculin test before or ≥1month after Dengvaxia vaccine.
Headache, inj site pain, malaise, asthenia, myalgia; hypersensitivity reactions, syncope.
Generic Drug Availability:
Single-dose vial—1 (w. diluent)